BioAtla Join Forces with Context Therapeutics to Develop and Commercialize BA3362 for Cancer Treatment
Shots:
- BioAtla & Context have signed an exclusive global licensing agreement to develop BA3362, with Context handling & funding all development & commercialization events of the candidate. Context also plans an IND filing for BA3362 in mid-2026
- BioAtla will get a total of $133.5M, which includes $15M upfront & near-term milestones, additional $118.5M clinical, development & commercial milestones plus net-sales-based tiered royalties
- BA3362 is a a CAB T cell engager that targets Nectin-4, overexpressed in various cancers. It is designed to activate primarily within the tumor microenvironment
Ref: BioAtla | Image: BioAtla & Context Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
